Raymond James upgraded Tectonic Therapeutics to Strong Buy and raised its price target to $81. Analyst highlights the potential of TX45 and TX2100 as two blockbuster candidates at a low valuation.
Lantheus is in talks to be bought by Curium for about $7B. No deal yet. Stock rose. Deal would be big in nuclear medicine.
FDA approves first HDV drug Hepcludex in US after prior rejection; lowers virus, but needs monitoring for safety risks.
Positive Phase 3 data shows Merck and Kelun’s sac-TMT combined with Keytruda reduced the risk of progression or death by 65% vs Keytruda alone in first-line PD-L1+ NSCLC.
Mizuho sees Q32 Bio upside with $14 target vs ~$5.50, boosted by bempikibart alopecia drug progress and 2026 data.
Experimental Parkinson’s drug BIIB122 failed to slow disease in trials despite strong biological effects; development stopped.
